CRISPR Therapeutics
CRISPR Therapeutics (NASDAQ: CRSP) is a clinical-stage biotechnology company founded in 2013 and headquartered in Zug, Switzerland, with US operations in Boston, Massachusetts. Co-founded by CRISPR/Cas9 pioneer Emmanuelle Charpentier, the company develops transformative gene-based medicines for serious human diseases. Its programs span hemoglobinopathies, immuno-oncology, regenerative medicine, and in-vivo editing; its lead therapy CASGEVY (exagamglogene autotemcel), developed with Vertex Pharmaceuticals, is the first approved CRISPR/Cas9 gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia. This is a corporate/investor web presence with no public developer program or API surface.
CRISPR Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Gene Editing, and CRISPR.
CRISPR Therapeutics’ developer surface includes support and 4 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 1
The organization behind the API